MRNS vs. IFRX, SCYX, MNOV, DERM, TPST, HOOK, JAGX, RLYB, CELU, and LPTX
Should you be buying Marinus Pharmaceuticals stock or one of its competitors? The main competitors of Marinus Pharmaceuticals include InflaRx (IFRX), SCYNEXIS (SCYX), MediciNova (MNOV), Journey Medical (DERM), Tempest Therapeutics (TPST), Hookipa Pharma (HOOK), Jaguar Health (JAGX), Rallybio (RLYB), Celularity (CELU), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical preparations" industry.
Marinus Pharmaceuticals (NASDAQ:MRNS) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, community ranking, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.
98.8% of Marinus Pharmaceuticals shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 5.5% of Marinus Pharmaceuticals shares are held by insiders. Comparatively, 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
InflaRx has a net margin of 0.00% compared to Marinus Pharmaceuticals' net margin of -513.80%. InflaRx's return on equity of -37.37% beat Marinus Pharmaceuticals' return on equity.
InflaRx has lower revenue, but higher earnings than Marinus Pharmaceuticals. InflaRx is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Marinus Pharmaceuticals has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.
In the previous week, Marinus Pharmaceuticals had 14 more articles in the media than InflaRx. MarketBeat recorded 28 mentions for Marinus Pharmaceuticals and 14 mentions for InflaRx. InflaRx's average media sentiment score of 0.73 beat Marinus Pharmaceuticals' score of 0.09 indicating that InflaRx is being referred to more favorably in the news media.
Marinus Pharmaceuticals presently has a consensus price target of $13.79, indicating a potential upside of 928.78%. InflaRx has a consensus price target of $13.50, indicating a potential upside of 844.06%. Given Marinus Pharmaceuticals' higher possible upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than InflaRx.
Marinus Pharmaceuticals received 193 more outperform votes than InflaRx when rated by MarketBeat users. Likewise, 69.27% of users gave Marinus Pharmaceuticals an outperform vote while only 64.19% of users gave InflaRx an outperform vote.
Summary
InflaRx beats Marinus Pharmaceuticals on 11 of the 19 factors compared between the two stocks.
Get Marinus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Marinus Pharmaceuticals Competitors List
Related Companies and Tools
